A new pill could be the future of treatment late-stage pancreatic cancer in the U.S., nearly doubling the length patients live compared to those on chemotherapy, clinical oncology company Revolution Medicines said Monday.
Pancreatic caner patients, who have some of the worst prognosis rates among all cancer patients, taking the once-daily drug daraxonrasib as part of a 500-person Phase 3 trial had a 60 percent reduced risk of death compared to those just on chemotherapy, suggesting the pill could be a more effective and less invasive route of treatment.
